<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-01830987</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-19T18:30:35+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial</title>
            <author role="aut">
              <persName>
                <forename type="first">Frederick J.</forename>
                <surname>Raal</surname>
              </persName>
              <idno type="halauthorid">1392511-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Evan A.</forename>
                <surname>Stein</surname>
              </persName>
              <idno type="halauthorid">1392512-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Robert</forename>
                <surname>Dufour</surname>
              </persName>
              <idno type="halauthorid">932231-0</idno>
              <affiliation ref="#struct-93263"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Traci</forename>
                <surname>Turner</surname>
              </persName>
              <idno type="halauthorid">1392513-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Fernando</forename>
                <surname>Civeira</surname>
              </persName>
              <idno type="halauthorid">1387910-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Lesley</forename>
                <surname>Burgess</surname>
              </persName>
              <idno type="halauthorid">1392514-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Gisle</forename>
                <surname>Langslet</surname>
              </persName>
              <idno type="halauthorid">1392515-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Russell</forename>
                <surname>Scott</surname>
              </persName>
              <idno type="halauthorid">936255-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Anders G.</forename>
                <surname>Olsson</surname>
              </persName>
              <idno type="halauthorid">1392516-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">David</forename>
                <surname>Sullivan</surname>
              </persName>
              <idno type="halauthorid">1392517-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">G. Kees</forename>
                <surname>Hovingh</surname>
              </persName>
              <idno type="halauthorid">1392518-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Bertrand</forename>
                <surname>Cariou</surname>
              </persName>
              <email type="md5">1eed1f2b671cbc31cf91c6a2af157d87</email>
              <email type="domain">univ-nantes.fr</email>
              <idno type="idhal" notation="numeric">761594</idno>
              <idno type="halauthorid" notation="string">410249-761594</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-1580-8040</idno>
              <idno type="IDREF">https://www.idref.fr/075934981</idno>
              <affiliation ref="#struct-182196"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Ioanna</forename>
                <surname>Gouni-Berthold</surname>
              </persName>
              <idno type="halauthorid">1392519-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Ransi</forename>
                <surname>Somaratne</surname>
              </persName>
              <idno type="halauthorid">983133-0</idno>
              <affiliation ref="#struct-361687"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Ian</forename>
                <surname>Bridges</surname>
              </persName>
              <idno type="halauthorid">1392520-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Rob</forename>
                <surname>Scott</surname>
              </persName>
              <idno type="halauthorid">983136-0</idno>
              <affiliation ref="#struct-361687"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Scott M.</forename>
                <surname>Wasserman</surname>
              </persName>
              <idno type="halauthorid">1392521-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Daniel</forename>
                <surname>Gaudet</surname>
              </persName>
              <idno type="halauthorid">1342474-0</idno>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Stephanie</forename>
                <surname>CHATEL</surname>
              </persName>
              <email type="md5">de2f31590e0d1c65e6348e5cd0c129d4</email>
              <email type="domain">univ-nantes.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2018-07-30 10:45:18</date>
              <date type="whenModified">2024-12-17 15:36:02</date>
              <date type="whenReleased">2018-07-30 10:45:19</date>
              <date type="whenProduced">2015-01</date>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="548802">
                <persName>
                  <forename>Stephanie</forename>
                  <surname>CHATEL</surname>
                </persName>
                <email type="md5">de2f31590e0d1c65e6348e5cd0c129d4</email>
                <email type="domain">univ-nantes.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-01830987</idno>
            <idno type="halUri">https://hal.science/hal-01830987</idno>
            <idno type="halBibtex">raal:hal-01830987</idno>
            <idno type="halRefHtml">&lt;i&gt;The Lancet&lt;/i&gt;, 2015, Equipe 5, 385 (9965), pp.331--340. &lt;a target="_blank" href="https://dx.doi.org/10.1016/S0140-6736(14)61399-4"&gt;&amp;#x27E8;10.1016/S0140-6736(14)61399-4&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">The Lancet, 2015, Equipe 5, 385 (9965), pp.331--340. &amp;#x27E8;10.1016/S0140-6736(14)61399-4&amp;#x27E9;</idno>
            <availability status="restricted"/>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="UNIV-NANTES">Université de Nantes</idno>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="THORAX-UMR">L'unité de recherche de l'institut du thorax (INSERM UMR1087, CNRS UMR6291)</idno>
            <idno type="stamp" n="NANTES-UNIVERSITE">Nantes Université</idno>
            <idno type="stamp" n="UNIV-NANTES-AV2022">Université de Nantes</idno>
            <idno type="stamp" n="UFR-MEDECINE-NANTES">UFR de médecine - Nantes Université</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Frederick J.</forename>
                    <surname>Raal</surname>
                  </persName>
                  <idno type="halauthorid">1392511-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Evan A.</forename>
                    <surname>Stein</surname>
                  </persName>
                  <idno type="halauthorid">1392512-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Robert</forename>
                    <surname>Dufour</surname>
                  </persName>
                  <idno type="halauthorid">932231-0</idno>
                  <affiliation ref="#struct-93263"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Traci</forename>
                    <surname>Turner</surname>
                  </persName>
                  <idno type="halauthorid">1392513-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Fernando</forename>
                    <surname>Civeira</surname>
                  </persName>
                  <idno type="halauthorid">1387910-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Lesley</forename>
                    <surname>Burgess</surname>
                  </persName>
                  <idno type="halauthorid">1392514-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Gisle</forename>
                    <surname>Langslet</surname>
                  </persName>
                  <idno type="halauthorid">1392515-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Russell</forename>
                    <surname>Scott</surname>
                  </persName>
                  <idno type="halauthorid">936255-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Anders G.</forename>
                    <surname>Olsson</surname>
                  </persName>
                  <idno type="halauthorid">1392516-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">David</forename>
                    <surname>Sullivan</surname>
                  </persName>
                  <idno type="halauthorid">1392517-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">G. Kees</forename>
                    <surname>Hovingh</surname>
                  </persName>
                  <idno type="halauthorid">1392518-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Bertrand</forename>
                    <surname>Cariou</surname>
                  </persName>
                  <email type="md5">1eed1f2b671cbc31cf91c6a2af157d87</email>
                  <email type="domain">univ-nantes.fr</email>
                  <idno type="idhal" notation="numeric">761594</idno>
                  <idno type="halauthorid" notation="string">410249-761594</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-1580-8040</idno>
                  <idno type="IDREF">https://www.idref.fr/075934981</idno>
                  <affiliation ref="#struct-182196"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Ioanna</forename>
                    <surname>Gouni-Berthold</surname>
                  </persName>
                  <idno type="halauthorid">1392519-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Ransi</forename>
                    <surname>Somaratne</surname>
                  </persName>
                  <idno type="halauthorid">983133-0</idno>
                  <affiliation ref="#struct-361687"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Ian</forename>
                    <surname>Bridges</surname>
                  </persName>
                  <idno type="halauthorid">1392520-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Rob</forename>
                    <surname>Scott</surname>
                  </persName>
                  <idno type="halauthorid">983136-0</idno>
                  <affiliation ref="#struct-361687"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Scott M.</forename>
                    <surname>Wasserman</surname>
                  </persName>
                  <idno type="halauthorid">1392521-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Daniel</forename>
                    <surname>Gaudet</surname>
                  </persName>
                  <idno type="halauthorid">1342474-0</idno>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">6710</idno>
                <idno type="issn">0140-6736</idno>
                <idno type="eissn">1474-547X</idno>
                <title level="j">The Lancet</title>
                <imprint>
                  <publisher>Elsevier</publisher>
                  <biblScope unit="serie">Equipe 5</biblScope>
                  <biblScope unit="volume">385</biblScope>
                  <biblScope unit="issue">9965</biblScope>
                  <biblScope unit="pp">331--340</biblScope>
                  <date type="datePub">2015-01</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1016/S0140-6736(14)61399-4</idno>
              <idno type="pubmed">25282519</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en"> heterozygote</term>
                <term xml:lang="en"> Hyperlipoproteinemia Type II</term>
                <term xml:lang="en"> Injections</term>
                <term xml:lang="en"> Drug Administration Schedule</term>
                <term xml:lang="en">Antibodies</term>
                <term xml:lang="en"> Monoclonal</term>
                <term xml:lang="en"> Anticholesteremic Agents</term>
                <term xml:lang="en"> Double-Blind Method</term>
                <term xml:lang="en"> Female</term>
                <term xml:lang="en"> Male</term>
                <term xml:lang="en"> Middle Aged</term>
                <term xml:lang="en"> adult</term>
                <term xml:lang="en"> humans</term>
                <term xml:lang="en"> Subcutaneous</term>
                <term xml:lang="en"> Serine Endopeptidases</term>
                <term xml:lang="en"> Proprotein Convertases</term>
                <term xml:lang="en"> Adolescent</term>
                <term xml:lang="en"> LDL</term>
                <term xml:lang="en"> Cholesterol</term>
                <term xml:lang="en"> Young Adult</term>
                <term xml:lang="en"> Treatment Outcome</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>BACKGROUND: Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature cardiovascular disease. Despite intensive statin therapy, with or without ezetimibe, many patients are unable to achieve recommended target levels of LDL cholesterol. We investigated the effect of PCSK9 inhibition with evolocumab (AMG 145) on LDL cholesterol in patients with this disorder. METHODS: This multicentre, randomised, double-blind, placebo-controlled trial was undertaken at 39 sites (most of which were specialised lipid clinics, mainly attached to academic institutions) in Australia, Asia, Europe, New Zealand, North America, and South Africa between Feb 7 and Dec 19, 2013. 331 eligible patients (18-80 years of age), who met clinical criteria for heterozygous familial hypercholesterolaemia and were on stable lipid-lowering therapy for at least 4 weeks, with a fasting LDL cholesterol concentration of 2·6 mmol/L or higher, were randomly allocated in a 2:2:1:1 ratio to receive subcutaneous evolocumab 140 mg every 2 weeks, evolocumab 420 mg monthly, or subcutaneous placebo every 2 weeks or monthly for 12 weeks. Randomisation was computer generated by the study sponsor, implemented by a computerised voice interactive system, and stratified by LDL cholesterol concentration at screening (higher or lower than 4·1 mmol/L) and by baseline ezetimibe use (yes/no). Patients, study personnel, investigators, and Amgen study staff were masked to treatment assignments within dosing frequency groups. The coprimary endpoints were percentage change from baseline in LDL cholesterol at week 12 and at the mean of weeks 10 and 12, analysed by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT01763918. FINDINGS: Of 415 screened patients, 331 were eligible and were randomly assigned to the four treatment groups: evolocumab 140 mg every 2 weeks (n=111), evolocumab 420 mg monthly (n=110), placebo every 2 weeks (n=55), or placebo monthly (n=55). 329 patients received at least one dose of study drug. Compared with placebo, evolocumab at both dosing schedules led to a significant reduction in mean LDL cholesterol at week 12 (every-2-weeks dose: 59·2% reduction [95% CI 53·4-65·1], monthly dose: 61·3% reduction [53·6-69·0]; both p\textless0·0001) and at the mean of weeks 10 and 12 (60·2% reduction [95% CI 54·5-65·8] and 65·6% reduction [59·8-71·3]; both p\textless0·0001). Evolocumab was well tolerated, with rates of adverse events similar to placebo. The most common adverse events occurring more frequently in the evolocumab-treated patients than in the placebo groups were nasopharyngitis (in 19 patients [9%] vs five [5%] in the placebo group) and muscle-related adverse events (ten patients [5%] vs 1 [1%]). INTERPRETATION: In patients with heterozygous familial hypercholesterolaemia, evolocumab administered either 140 mg every 2 weeks or 420 mg monthly was well tolerated and yielded similar and rapid 60% reductions in LDL cholesterol compared with placebo. FUNDING: Amgen Inc.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="institution" xml:id="struct-93263" status="OLD">
          <idno type="IdRef">026403447</idno>
          <idno type="ROR">https://ror.org/03gnr7b55</idno>
          <orgName>Université de Nantes</orgName>
          <orgName type="acronym">UN</orgName>
          <date type="end">2021-12-31</date>
          <desc>
            <address>
              <addrLine>1, quai de Tourville - BP 13522 - 44035 Nantes cedex 1</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-nantes.fr/</ref>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-182196" status="OLD">
          <idno type="IdRef">190708026</idno>
          <idno type="RNSR">201220396X</idno>
          <orgName>ITX - unité de recherche de l'institut du thorax</orgName>
          <orgName type="acronym">ITX</orgName>
          <date type="start">2012-01-01</date>
          <date type="end">2021-12-31</date>
          <desc>
            <address>
              <addrLine>8 quai Moncousu - BP 70721 - 44007 Nantes Cedex 1</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.umr1087.univ-nantes.fr/</ref>
          </desc>
          <listRelation>
            <relation name="U1087" active="#struct-303623" type="direct"/>
            <relation name="UMR6291" active="#struct-441569" type="direct"/>
            <relation active="#struct-531638" type="direct"/>
            <relation active="#struct-93263" type="indirect"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-361687" status="VALID">
          <orgName>Applied Molecular Genetics</orgName>
          <orgName type="acronym">AMGen</orgName>
          <date type="start">1980-01-01</date>
          <desc>
            <address>
              <addrLine>Arcs de Seine18-20 Quai du Point du Jour92100 Boulogne Billancourt</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.amgen.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
        <org type="regrouplaboratory" xml:id="struct-531638" status="OLD">
          <idno type="IdRef">076954927</idno>
          <orgName>Université de Nantes - UFR de Médecine et des Techniques Médicales</orgName>
          <orgName type="acronym">UFR MEDECINE</orgName>
          <date type="end">2021-12-31</date>
          <desc>
            <address>
              <addrLine>1 rue Gaston Veil BP 53508 44035 NANTES Cedex 1</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.medecine.univ-nantes.fr</ref>
          </desc>
          <listRelation>
            <relation active="#struct-93263" type="direct"/>
          </listRelation>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>